The commercial debate in medium-sized electrical materials companies habitually concentrates on the site: how to compete on price, how to gain distribution share, how to defend the product against alternatives. Global leaders in the sector dedicate a good part of their effort to a different conversation, prior to the site, where the brand and product are incorporated into the project before the buyer has a decision to make.
An industrial or tertiary electrical project passes through a technical prescription phase where an engineering firm, a project designer, a specialist installer or a consultant defines the solution, dimensions the equipment and, in many cases, specifies the preferred brand. That work occurs months before the site and, except for exceptions, outside the reach of the medium-sized manufacturer's habitual commercial officer.
When the site begins, what is being competed for is no longer the entire project. What is being competed for is the substitution of the specified product for an equivalent alternative, frequently cheaper. That battle, fought by the habitual commercial team, is structurally unfavourable for the manufacturer who arrived late to the technical phase. It competes against a preference already installed in whoever is going to assemble the installation.
The technical concept that articulates the difference is the distinction between prescription and specification. To specify means to comply with a set of technical requirements published in a tender document. To prescribe means to be incorporated into the project as the preferred brand from the outset. Specification is open competition. Prescription is competition already won before starting.
The observable pattern in sector leaders is that they invest in a sustained manner in their technical prescription teams, which work with engineering firms, installers and consultants on project design before concrete opportunities exist. That investment does not produce visible pipeline in the quarter, but it produces future share over twelve- to twenty-four-month horizons.
Three levers define a functional prescription system. A team of technical prescribers assigned by client type and geography, with relationship responsibility and specific metrics distinct from those of the habitual commercial officer. An editorial system of technical documentation useful for the project designer, not for the buyer, with design guides, resolved cases and reusable templates. And a follow-up mechanism for specified projects that protects the prescribed brand during the site phase, avoiding substitution in the last mile.
The frequent error of the medium-sized manufacturer consists in assuming that prescription is a natural function of the commercial team. It is only partly so. The commercial officer visits the installer or distributor when there is a site. The prescriber visits the project designer when there is not yet a site. They are two distinct disciplines requiring different capabilities, metrics and agendas.
The consequences are of three types. Budgetary allocation must distinguish between investment in active site capture and investment in prior technical prescription, with different criteria and metrics for each function. The organisational structure must contemplate profiles dedicated to prescription, not shared with the habitual sales force. And the commercial dashboard requires specific indicators of prescription health, distinct from closing indicators.
The habitual objection is that investment in prescription does not yield measurable return in the short term. The objection correctly describes the pace, not the magnitude. Prescription yields over horizons that coincide with the average cycle of relevant projects. To renounce it because of its latency is to renounce the lever that most differentiates organic growth between leaders and medium-sized firms.
What separates the medium-sized manufacturer from the leader in electrical materials is not product. It is the layer where it competes. The one that competes only on site captures a fraction of the value. The one that also competes in technical prescription decides the greater part of the operation before the site begins.